Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines
K Chen, L Zhang, Z Fang, J Li, C Li, W Song… - Frontiers in …, 2023 - frontiersin.org
By the end of 2022, different variants of Omicron had rapidly spread worldwide, causing a
significant impact on the Coronavirus disease 2019 (COVID-19) pandemic situation …
significant impact on the Coronavirus disease 2019 (COVID-19) pandemic situation …
Design, structure and plasma binding of ancestral β-CoV scaffold antigens
D Hueting, K Schriever, R Sun, S Vlachiotis… - Nature …, 2023 - nature.com
We report the application of ancestral sequence reconstruction on coronavirus spike protein,
resulting in stable and highly soluble ancestral scaffold antigens (AnSAs). The AnSAs …
resulting in stable and highly soluble ancestral scaffold antigens (AnSAs). The AnSAs …
Breakthrough SARS-CoV-2 Omicron variant in individuals primed with heterologous vaccines enhances inhibition performance of neutralizing antibody to BA. 2 …
J Szekely, P Swangphon, N Nanakorn, P Chaimuti… - Vaccines, 2023 - mdpi.com
This study aims to analyze the neutralization ability against Omicron parental variants in five
clusters of individuals with different Coronavirus disease (COVID-19) immunity …
clusters of individuals with different Coronavirus disease (COVID-19) immunity …
Neutralisation activity of mucosal IgA against XBB sublineages and BA. 2.86
Recent publications in The Lancet Infectious Diseases have reported a marked decrease in
neutralisation activity against the current SARS-CoV-2 omicron subvariants, such as XBB …
neutralisation activity against the current SARS-CoV-2 omicron subvariants, such as XBB …
Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study
D Peng, L Yang, C Jin, J Feng, M Cao, Y Liu - Heliyon, 2024 - cell.com
Objective To further explore the effect of vaccination regimen and frequency on clinical
outcomes of breakthrough infections caused by the Omicron variant, as well as the durability …
outcomes of breakthrough infections caused by the Omicron variant, as well as the durability …
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized …
M Salehi, IA Darazam, A Nematollahi… - International …, 2024 - Elsevier
The recurrent COVID-19 infection, despite global vaccination, highlights the need for booster
doses. A heterologous booster has been suggested to enhance immunity and protection …
doses. A heterologous booster has been suggested to enhance immunity and protection …
Safety and immunogenicity of COReNAPCIN®, a SARS-CoV-2 mRNA vaccine; a randomized, double-blind, placebo-controlled phase 1 clinical trial
M Salehi, IA Darazam, A Nematollahi… - medRxiv, 2023 - medrxiv.org
The repeated COVID-19 outbreaks, despite global vaccination, highlights the need for
booster doses. Here, we present the outcomes, up until day 90 post vaccination, of a …
booster doses. Here, we present the outcomes, up until day 90 post vaccination, of a …